百济神州2024年业绩解析:创新药驱动高增长,全球化战略重塑竞争格局

新浪证券
03 Mar

2024年,百济神州(688235.SH)交出了一份营收与亏损同步改善的业绩快报:全年实现营业收入272.14亿元,同比增长56.2%;净利润亏损收窄至49.78亿元,同比减少25.87%。这一成绩背后,是公司核心产品在全球市场的爆发式增长、研发管线的持续突破,以及全球化战略的深化推进。本文将从行业趋势、产品竞争力和未来空间等角度,解析百济神州的成长逻辑与潜在风险。创新药全球化加速,中国药企迎来“...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10